Loading…
It is a non-randomized, open-label phase II treatment trial (single group assignment) evaluating CP101 in adults with Clostridioides difficile infection (CDI) (recurrent)
Number of Participants With Absence of Recurrence Through Week 8 Based on Adjudication, safety
No published results found as of June 2026